biote (BTMD) Stock Price, News & Analysis

Company Overview

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

Key Stats

• Today's Range: $2.18 to $2.34
• 50-Day Range: $1.67 to $2.46
• 52-Week Range: $1.27 to $4.75
• Volume: 193,986 shs
• Average Volume: 395,637 shs
• Market Capitalization: $82.30 million
• P/E Ratio: 4.98
• Dividend Yield: N/A
• Price Target: $2.75
• Consensus Rating: Moderate Buy

biote Stock Analysis - MarketRank™

biote scored higher than 94% of companies evaluated by MarketBeat, and ranked 55th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

biote has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

biote has a consensus price target of $2.75, representing about 25.6% upside from its current price of $2.19.

Amount of Analyst Coverage

biote has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 47.22%

Earnings Growth

Earnings for biote are expected to grow by 47.22% in the coming year, from $0.36 to $0.53 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of biote is 5.27, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.25.

Price to Earnings Ratio vs. Sector

The P/E ratio of biote is 5.27, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.04.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.18% of the float of biote has been sold short.

Short Interest Ratio / Days to Cover

biote has a short interest ratio ("days to cover") of 0.89, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in biote has recently decreased by 56.99%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

biote does not currently pay a dividend.

Dividend Growth

biote does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.37

News Sentiment

biote has a news sentiment score of 1.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for biote this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, biote insiders have not sold or bought any company stock.

Percentage Held by Insiders

32.40% of the stock of biote is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

21.68% of the stock of biote is held by institutions.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 7/14/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BTMD
• CIK: 1819253
• Web: biote.com
• Phone: 844-604-1246
• Fax: 212-616-9601
• Employees: 194
• Year Founded: N/A

Price Target and Rating

• Average Price Target for biote: $2.75
• High Price Target: $4.00
• Low Price Target: $2.00
• Potential Upside/Downside: +25.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.44
• Trailing P/E Ratio: 4.98
• Forward P/E Ratio: 6.08
• P/E Growth: N/A
• Net Income: $27.05 million
• Net Margins: 8.29%
• Pretax Margin: 12.47%
• Return on Equity: -25.72%
• Return on Assets: 15.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.29
• Quick Ratio: 0.58

Sales & Book Value

• Annual Sales: $192.22 million
• Price / Sales: 0.43
• Cash Flow: $0.55 per share
• Price / Cash Flow: 4.00
• Book Value: ($1.40) per share
• Price / Book: -1.56

Miscellaneous

• Outstanding Shares: 37,580,000
• Free Float: 25,405,000
• Market Cap: $82.30 million
• Optionable: Not Optionable
• Beta: 1.66